Contents
The European Medicines Agency released a statement on the Johnson & Johnson vaccine on Wednesday. The benefits of this vaccine in preventing COVID-19 outweigh the risk of side effects, the release reads. Doubts about this preparation are related to cases of thrombosis that occurred in vaccinated people in the United States.
- Six cases of bleeding disorders have been reported in the US following the administration of the COVID-19 vaccine from Johnson & Johnson
- The American CDC and the FDA called for the suspension of vaccination with this preparation
- Vaccination with this vaccine has not yet begun in Europe
- The manufacturer has announced that it will delay deliveries to European countries, however, they are to reach Poland as previously planned – the first delivery on April 14
- You can find more up-to-date information on vaccinations against COVID-19 on the Onet homepage.
EMA: The benefits of the Johnson & Johnson vaccine outweigh the risks of side effects
The benefits of the Johnson & Johnson vaccine in preventing COVID-19 outweigh the risk of side effects, the European Medicines Agency (EMA) said on Wednesday. Earlier in the US, vaccinations with the company’s preparation were suspended to test for rare blood clots.
“As announced last week, the EMA’s safety committee (PRAC) is investigating very rare cases of unusual blood clots that have occurred in the United States following the use of the J&J COVID-19 vaccine. The type of blood clot reported, cerebral vein thrombosis (CVST), was in most cases combined with a low platelet count (thrombocytopenia), »reads the EMA statement sent to the media.
Johnson & Johnson vaccine withheld in the US
On Tuesday, the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) recommended that the administration of the J&J vaccine be suspended due to six cases of blood clots among 6,8 million vaccinated people.
The company itself, in turn, announced a decision to “proactively delay the introduction of the vaccine in the EU”. The vaccine was authorized in the EU on March 11, but its widespread use has not yet started.
- USA: CDC and FDA call to stop vaccination with Johnson & Johnson
“EMA is investigating all reported cases and will decide if regulatory action is needed. (…) The agency is accelerating this assessment and now expects to make a recommendation next week. While the review is ongoing, EMA still believes that the benefits of the vaccine in preventing Covid-19 outweigh the risk of side effects. The Agency’s scientific advice provides EU Member States with the information they need to make decisions about the use of vaccines in their national vaccination campaigns, »concludes the EMA.
From Brussels Artur Ciechanowicz (PAP)
You may be interested in:
- Are there groups of patients who should not be vaccinated with AstraZeneca?
- AstraZenecę vaccinations safe in inflammatory diseases of the joints? The Polish Society of Rheumatologists responds
- How do I deal with the side effects of vaccination? [WE EXPLAIN]
The content of the medTvoiLokony website is intended to improve, not replace, the contact between the Website User and their doctor. The website is intended for informational and educational purposes only. Before following the specialist knowledge, in particular medical advice, contained on our Website, you must consult a doctor. The Administrator does not bear any consequences resulting from the use of information contained on the Website. Do you need a medical consultation or an e-prescription? Go to halodoctor.pl, where you will get online help – quickly, safely and without leaving your home.Now you can use e-consultation also free of charge under the National Health Fund.